<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107950</url>
  </required_header>
  <id_info>
    <org_study_id>SOV02</org_study_id>
    <secondary_id>2013-001323-38</secondary_id>
    <nct_id>NCT02107950</nct_id>
  </id_info>
  <brief_title>Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma</brief_title>
  <official_title>A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy
      (carboplatin and gemcitabine as second line chemotherapy) may result in prolongation of
      progression free survival (PFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether DCVAC/OvCa added to Standard of Care
      chemotherapy (carboplatin and gemcitabine as second line chemotherapy) may result in
      prolongation of progression free survival (PFS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine median progression free survival</measure>
    <time_frame>72 Week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (all causes)</measure>
    <time_frame>56, 64, 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>8, 16, 24, 32, 40, 48, 56. 64. 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Progression Free Interval</measure>
    <time_frame>6, 12, 18, 24, 36, 42, 48, 56, 64, 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological Response</measure>
    <time_frame>24, 48, 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>8, 16, 24, 32, 40, 48, 56. 64. 72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Ovarian Cancer (OvCa)</condition>
  <condition>Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC/OvCa in parallel with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with DCVAC/OvCa and Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care carboplatin and gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/OvCa in parallel with chemotherapy</intervention_name>
    <description>DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine</description>
    <arm_group_label>DCVAC/OvCa in parallel with chemotherapy</arm_group_label>
    <other_name>DCVAC/OvCa</other_name>
    <other_name>carboplatin and gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Carboplatin and Gemcitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females 18 years old and older

          -  Patients with histologically confirmed, International Federation of Gynecology and
             Obstetrics (FIGO) stage III or IV epithelial ovarian, primary peritoneal or fallopian
             tube carcinoma (serous, endometrioid or mucinous), who had complete remission after
             first line platinum (Pt)-based chemotherapy and are selected to receive second line
             Standard of Care chemotherapy

          -  Radiologically confirmed relapse after &gt;6 months of remission (Platinum-sensitive
             patients), found up to 4 weeks prior study entry.

          -  The patient must have at least one measureable target lesion as defined by the
             Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria to be eligible for
             enrolment in the study

        Exclusion Criteria:

          -  FIGO I,II epithelial ovarian cancer

          -  FIGO III, IV clear cells epithelial ovarian cancer

          -  Non-epithelial ovarian cancer

          -  Borderline tumors (tumors of low malignant potential)

          -  Prior or current systemic anti-cancer therapy for ovarian cancer [for example
             chemotherapy, monoclonal antibody therapy , tyrosine kinase inhibitor therapy,
             vascular endothelial growth factor (VEGF) therapy or hormonal therapy] except first
             line Platinum-based chemotherapy (with or without bevacizumab)

          -  Previous radiotherapy to the abdomen and pelvis

          -  Malignancy other than epithelial ovarian cancer, except those that have been in
             clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the
             cervix or non-melanoma skin carcinomas
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ales Horacek</last_name>
    <role>Study Director</role>
    <affiliation>Accord Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nový Jičín</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>755 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91 054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian</keyword>
  <keyword>Platinum Sensitive</keyword>
  <keyword>Epithelial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>will be posted to EMA website</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

